Skip Navigation

European Heart Journal 1995 16(Supplement N):46-51; doi:10.1093/eurheartj/16.suppl_N.46
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smits, J. F. M.
Right arrow Articles by Daemen, M. J. A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smits, J. F. M.
Right arrow Articles by Daemen, M. J. A. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Does ACE inhibition limit structural changes in the heart following myocardial infarction?

J. F. M. Smits, R. C. J. J. Passier, H. J. M. G. Nelissen-Vrancken, J. P. M. Cleutjens*, M. C. Kuizinga* and M. J. A. P. Daemen*

Department of Pharmacology, Cardiovascular Research Institute Maastricht, University of Limburg Maastricht, The Netherlands
* Department of Pathology, Cardiovascular Research Institute Maastricht, University of Limburg Maastricht, The Netherlands

Correspondence: Jos F. M. Smits, Department of Pharmacology, Cardiovas cular Research Institute Maastricht, University of Limburg, P.O. Box 616, 6200MD Maanstricht, The Netherlands

A recent series of experiments in our laboratory were designed to elucidate the cellular changes that underlie the cardiac remodelling response following myocardial infarction (MI) in the rat as well as the potential role of the renin-angiotensin system (RAS) in this response. Inhibition of the RAS interferes with cardiomyocyte hypertrophy, interstitial cell DNA synthesis, and collagen deposition, these effects are mediated through the angiotensin II AT1 receptor subtype. Also, vascular outgrowth is functionally diminished, an effect that seems to depend on AT2 receptor activation. The intracardiac RAS may be involved in the wound healing response in the infarct area. However, we found no evidence for activation of the RAS in the remnant myocardium, which suggests that myocyte hypertrophy and interstitial fibrosis depend on activation of the systemic RAS. During the first weeks following MI, therapy of choice should thus inhibit the systemic RAS while allowing the wound-healing response of the intracardiac RAS, i e. selective AT1 antagonists are appropriate early after MI. AT2 antagonists administered at that time can inhibit the cardiac vascularization response and cause a further decrease in level of cardiac function.

Key Words: Myocardial infarction • cardiac renin-angiotensin system • systemic renin-angiotensin system • cardiac structural change • AT receptor antagonists • ACE inhibitors • myocyte hypertrophy • interstitial fibrosis • collagen deposition • wound healing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.